Launch Price and Access Report: Drug Approvals from 2022-2025

ICER and West Health developed the 2026 “Launch Price and Access Report”, an independent analysis of drug prices and patient access for newly launched FDA-approved treatments. This Launch Price and Access Report analyzes launch price trends over four years (2022-2025). It also includes an in-depth review of patient access to newly launched drugs using real-world pharmacy and medical claims data, and payer coverage policies.

Key takeaways include

• Only about one in three newly approved drugs previously reviewed by ICER were priced at or below ICER’s recommended price benchmark, with the remainder exceeding their estimated value.

• The median annual net launch price reached $257,000 in 2025.

• About 1 in 4 drugs launched in 2025 had annual net prices above $500,000.

• Only about one-third of outpatient prescriptions for newly launched drugs were filled within 30 days.

Read the full report explore the latest trends in new drug prices and access, and the case for better aligning prices with value.